Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 10/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794676 | 0.92 | PDE1B (0.40) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL24263381 | 0.91 | PDE1B (0.39) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL16812352 | 0.89 | PDE1B (0.38) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL16794693 | 0.88 | MAPT (0.42) | PDE1BALDH1A1HTTSMN1; SMN2MEN1 | |
| SCHEMBL16812355 | 0.88 | ALDH1A1 (0.39) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL16812493 | 0.88 | NR3C1 (0.39) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL29754326 | 0.85 | PTPN1 (0.38) | PDE1BALDH1A1HTTSMN1; SMN2NR3C1 | |
| SCHEMBL16794653 | 0.85 | CNR2 (0.41) | ALDH1A1 | |
| SCHEMBL16812354 | 0.85 | CDK5 (0.39) | PDE1BSMN1; SMN2NR3C1MEN1KMT2A | |
| SCHEMBL16812486 | 0.85 | NPC1 (0.40) | PDE1BALDH1A1SMN1; SMN2NR3C1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780842-B2 | TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780842-B2 | TYK2 pseudokinase ligands | TYK2, JAK2, PTK2B | PDE1B 1977/4885ALDH1A1 4812/4885HTT 2189/4885 |
| US-20160304524-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA RESPONSES | TYK2, IFNAR1, JAK3 | PDE1B 1789/4885ALDH1A1 3902/4885HTT 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.